Robin Carhart-Harris

And yeah, there was a period of some correction, you might say.

There was a bit of a pushback on this space for different reasons.

And I think there was a market correction as well.

Some of the psychedelic medicine companies had gone up to a

pretty high valuation, a couple of billion dollars, I think, one of them.

And they're certainly not there now.

So something's happened.

We had Lycos seemingly close to getting FDA approval for MDMA therapy for post-traumatic stress disorder, but that was denied by the regulators, by the FDA.

And so that put it

dent in the road.

I do think that there are reasons to be optimistic, though.

If you look at the research, there's a heck of a lot of research.

I mean, there's more than ever.

The publication, you know, rate and volume is higher than ever year on year.

And, you know, more quality trials, bigger trials.

So I still feel that, yeah, we're knocking on the door of

If FDA approval is the prime milestone, I still think that that's achievable and probably quite close.

Yeah.

So what's your sense of all of the research to date that we're relying on to kind of organize our intuitions about the therapeutic value of psychedelics?

I mean, much of it, I think, is probably underpowered and many things probably haven't been replicated.